Frankfurt, 11 February 2026 – MFI (Moving Forward International GmbH), part of the PHSE Group since October 2024, announces the acquisition of TKS, a German specialist transport company focused on dangerous goods, radioactive materials and radiopharmaceutical products.
TKS brings significant operational capacity to MFI, with experienced drivers and administrative staff, and a fleet of specialized vehicles. The company is strategically headquartered near Frankfurt Airport, Germany’s principal aviation hub and one of Europe’s largest cargo centers, providing optimal connectivity for time-critical pharmaceutical shipments.
The acquisition strengthens MFI’s transport capabilities across key European markets, with TKS operations spanning Germany, Austria, Czech Republic, France, the Netherlands, and Belgium. TKS bringing expert knowledge and specific specialist licenses that are essential for handling these highly sensitive materials.
“Strengthening our German transport operations while enhancing our global Nuclear Medicine capabilities represents a strategic priority for PHSE“, said Fabio Mioli, CEO of PHSE International.. “TKS’s integration delivers specialized expertise and infrastructure that align precisely with our long-term expansion strategy in radiopharmaceutical logistics. As worldwide demand in this sector continues its rapid growth trajectory, we are positioning ourselves to deliver the world-class, time-critical solutions that patients and pharmaceutical partners depend upon.”
The integration will see Andreas Rückfert, TKS’s experienced leader, assume the role of Head of Trasport Division for MFI Germany, bringing invaluable transport expertise to the enlarged operation.
“I am very pleased to become part of the MFI business, which I have admired for some time, and to join the wider PHSE Group with all the knowledge and expertise it has to offer”, commented Andreas Rückfert. “This partnership will enable us to leverage our combined capabilities to better serve our customers across Europe.”
With this transaction, the PHSE Group reinforces its position as a leading specialist in radiopharmaceutical logistics, a critical sector where highly sensitive oncology therapeutics and nuclear medicine diagnostics demand absolute precision and uncompromised speed in delivery.
